Nkarta, Inc.
🏢 View company profile →7Patents
7Active
7Granted
49Portfolio score
Filing activity: Mar 27, 2018 → May 10, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11365236B2 | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy | Chemistry; Metallurgy | 6 | Active |
| US11253547B2 | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | Chemistry; Metallurgy | 6 | Active |
| US11141436B2 | Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | Chemistry; Metallurgy | 4 | Active |
| US11154575B2 | Cancer immunotherapy using CD19-directed chimeric antigen receptors | Chemistry; Metallurgy | 4 | Active |
| US12012458B2 | Genetically modified natural killer cells for CD70-directed cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US12351617B2 | Immune cells comprising truncated NKG2D chimeric receptors | Chemistry; Metallurgy | 0 | Active |
| US12398187B2 | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.